Monogram Technologies Acquisition and Autonomous Robotics Innovation
Zimmer Biomet announced the acquisition of Monogram Technologies on July 14, which is behind the mBôs robot with semi and fully autonomous AI-driven capabilities.
Monogram's robot became the first in the world to complete a fully autonomous surgery using its implants, highlighting its disruptive potential.
The acquisition aims to complement Zimmer Biomet's existing robotic solutions like ROSA and to position the company as a leader in autonomous orthopedic surgery.
Management emphasized the strategic importance of autonomous robotics, with plans to launch semi-autonomous systems in early 2027 and fully autonomous systems by late 2027 or early 2028.
The technology features AI, machine learning, markerless tracking, and remote surgery capabilities, which are expected to significantly improve precision, reduce surgeon fatigue, and enhance scalability.
Seer launched the Proteograph ONE workflow and SP200 automation instrument in June, marking a major inflection point for large-scale proteomics research.
The new workflow more than doubled throughput to over 1,000 samples per week, with a 30% reduction in run time to approximately 4.5 hours, enabling high-volume studies.
Feedback from key opinion leaders (KOLs) has been highly positive, with early data presentations at industry conferences demonstrating the technology's potential for large population studies.
Proteograph ONE allows identification of up to 10x more proteins than traditional workflows, with improved precision and potential cost reductions per sample.
The launch has already facilitated large-scale population studies, including a 20,000 sample study with Korea University and a 10,000 sample study with Discovery Life Sciences.
Dafinchi